PA
ARQT icon

Parallel Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Parallel Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11K Buy
47
+45
+2,250% +$1.15K ﹤0.01% 3522
2025
Q4 		$58 Buy
+2
New +$51 ﹤0.01% 3567
2025
Q2 		– Sell
-14
Closed -$219 – 3551
2025
Q1 		$219 Sell
14
-14
-50% -$197 ﹤0.01% 3368
2024
Q4 		$390 Buy
+28
New +$307 ﹤0.01% 3269
2023
Q3 		– Sell
-32
Closed -$305 – 3369
2023
Q2 		$305 Buy
+32
New +$355 ﹤0.01% 3192
2022
Q3 		– Sell
-7
Closed – – 3127
2022
Q2 		$0 Buy
+7
New +$144 ﹤0.01% 2978

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return